Every 10-Q that Trimas Corp (TRS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRS filings page.
TriMas Corporation completed the sale of its Aerospace segment for approximately $1,456.9 million in cash, recognizing a pre-tax gain of $1,040.0 million. Net proceeds were $1,241.8 million, lifting cash and cash equivalents to $1,242.5 million at June 30, 2026 and expanding retained earnings to $917.0 million.
For continuing operations, second-quarter 2026 net sales were $174.6 million, up slightly from 2025, with Specialty Products growing and Packaging modestly lower organically. Operating profit rose to $10.9 million, aided by lower corporate costs but offset by $2.1 million of realignment charges and weaker Specialty Products margins. Six‑month income from continuing operations increased to $15.5 million, while total net income reached $814.2 million including discontinued operations.
The company used its stronger balance sheet to repay revolving credit borrowings, leaving only the $400.0 million senior notes outstanding (long‑term debt net $396.9 million). It also returned capital via $73.5 million of share repurchases and $0.04 per‑share quarterly dividends, with $76.5 million remaining under its buyback authorization. An income tax provision misallocation in early 2026 was corrected as an out‑of‑period adjustment between continuing and discontinued operations without changing total tax expense.
TriMas Corporation transformed its balance sheet in early 2026 by completing the sale of its Aerospace segment for approximately $1,456.9 million in cash, generating net proceeds of $1,241.8 million and a pre-tax gain of $1,040.0 million. This drove Q1 2026 net income to $800.8 million, while income from continuing operations showed a loss of $51.8 million as a $54.3 million tax charge, including $53.9 million tied to the divestiture’s deferred tax reclassification, outweighed modest operating profit.
Net sales from continuing operations rose 10.4% year over year to $168.3 million, with Packaging at $139.2 million and Specialty Products at $29.1 million. Specialty Products swung from an operating loss to profit on stronger steel cylinder demand. Packaging grew but saw margin pressure from mix and $4.1 million of realignment costs.
TriMas ended March 31, 2026 with $1,309.6 million of cash and cash equivalents invested mainly in highly liquid instruments earning about 3.5%, against $400.0 million of 4.125% Senior Notes and no revolver borrowings. The company repurchased 1.49 million shares for $54.5 million, paid a $0.04 per-share dividend, and retained $95.5 million of remaining buyback authorization. Asbestos-related liabilities stood at $35.1 million, largely offset by a $34.3 million insurance recovery asset.
TriMas (TRS) reported stronger Q3 2025 results, with net sales of $269.3 million, up from $229.4 million a year ago. Net income rose to $9.3 million ($0.23 diluted EPS) versus $2.5 million ($0.06) as operating profit improved and interest expense declined. For the nine months, sales reached $785.7 million and net income was $38.4 million ($0.94 diluted EPS).
Aerospace led growth, with Q3 sales of $103.2 million vs. $70.8 million, aided by the GMT Aerospace acquisition for $37.7 million. The Company also completed the sale of its Arrow Engine business for $21.0 million, recording a $5.4 million gain year‑to‑date.
Cash generation and balance sheet: net cash from operating activities was $75.9 million year‑to‑date; capital expenditures were $43.7 million. Long‑term debt was $407.1 million, including $400.0 million of 4.125% Senior Notes due 2029. The revolving credit facility was amended to $250.0 million maturing on 3/31/2030, with $10.9 million outstanding and $233.1 million available at quarter‑end.
The Company recorded an $8.0 million asbestos remeasurement, increasing the asbestos liability to $36.6 million, and began transitioning certain asbestos costs to excess insurance coverage. Shares outstanding were 40,642,475 as of September 30, 2025.